To look at the clinical significance of co-occurring FOXP1-SHQ1 and PTEN loss more broadly across cancer types, we asked whether combined FOXP1-SHQ1 and PTEN loss was associated with cancer recurrence in all TCGA cohorts with co-enriched FOXP1-SHQ1 and PTEN loss. This evidence concerns the gene SHQ1 and cancer.